Advice for Dermatologists in Treating Psoriasis in Patients With Skin of Color
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share advice for improving psoriasis care for patients with skin of color.
Read More
Data With Biologics in Patients With Skin of Color
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share how they utilize biologics data from skin of color cohorts in their practice.
Early Use of Systemic Treatments in Patients With Skin of Color
Drs Stein Gold and Desai share their thoughts on the early use of psoriasis systemic treatments in patients with skin of color.
Results of VISIBLE Trial in Patients With Skin of Color
Dermatology experts highlight VISIBLE trial results when using guselkumab in patients with skin of color.
Guselkumab in Patients With Skin of Color: VISIBLE Trial Design
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai discuss VISIBLE trial, a randomized clinical trial specifically designed to examine treatment outcomes with guselkumab in patients with skin of color.
Traditional Systemic Therapy for Psoriasis for Patients With Skin of Color
Drs Desai, Shahriari, and Stein Gold examine use and place of traditional systemic treatments in psoriasis.
Topical Treatments for Psoriasis for Patients With Skin of Color
Dr Stein Gold and Dr Shahriari review steroidal and non-steroidal topical treatments that are available for use in psoriasis.
Post-Inflammatory Dyspigmentation in Patients With Skin of Color
Dr Linda Stein Gold and Dr Mona Shahriari discuss post-inflammatory dyspigmentation in patients with skin of color and its impact on patient’s quality of life.
Communicating With Patients With Psoriasis With Skin of Color
2 expert dermatologists provide tips for communicating, in a culturally sensitive manner, with patients with skin of color.
Social and Cultural Stigma of Psoriasis in Patients With Skin of Color
Drs Stein Gold, Shahriari and Desai highlight social and cultural stigma of psoriasis in patients with skin of color and its impact on patient’s quality of life.
Presentation of and Challenges in Treatment of Psoriasis in Patients With Skin of Color
Expert dermatologists review the presentation of psoriasis in patients with skin of color and the challenges physicians face in diagnosing psoriasis in this patient population.
Advances in oHCM Therapy
Milind Desai, MD, MBA, comments on the broadening knowledge in the oHCM space, leading to the development of new therapies.
Septal Reduction Therapies in oHCM
Expert cardiologists share approaches to the challenges that come with septal reduction therapy, as well as access to oHCM treatment.
Key Takeaways on Vitiligo Management
Expert dermatologists share final thoughts on treatment of vitiligo and topical ruxolitinib.
Promoting Access to New Therapies in Vitiligo
Experts in dermatology comment on the need to promote access to emerging treatments in vitiligo.
Managing Vitiligo Patient Expectations
Heather Woolery-Lloyd, MD, and Nada Elbuluk, MD, share approaches to patient education and managing patient expectations when repigmenting the skin in vitiligo.
Disease Burden for Patients With Vitiligo
Expert dermatologists discuss the impact of vitiligo and vitiligo treatment on quality of life.
Treatment Response to Conventional vs Emerging Therapies in Vitiligo
Nada Elbuluk, MD, and Ted Lain, MD, compare response to conventional treatment options vs emerging therapies, such as ruxolitinib, in the treatment of vitiligo.
Treatment Approaches to Ruxolitinib in Vitiligo
Experts in dermatology share their impressions of ruxolitinib and approaches to vitiligo treatment in clinical practice.
Adverse Events of Ruxolitinib in Vitiligo Trials
Heather Woolery-Lloyd, MD, discusses the adverse event profile of topical ruxolitinib for treatment of vitiligo, highlighting the well-tolerated nature of the drug.
Impact of UV Light Exposure on Vitiligo
Expert dermatologists comment on the impact of UV light exposure on areas of the skin with vitiligo and their recommendations for sunscreen use.
Use of Ruxolitinib for Treatment of Vitiligo
Experts in dermatology review the mechanism of action and clinical trials of topical ruxolitinib for repigmenting the skin in vitiligo.
Measuring Vitiligo Treatment Response
Brittany Craiglow, MD, discusses the lengthy nature of vitiligo treatment response and how to approach communicating with patients who want to see change quickly.
Mechanism of Repigmentation in Vitiligo
Ted Lain, MD, reviews the rates and patterns of repigmentation of the skin in vitiligo and how the timeline is different for each patient.
Treatment Goals in Vitiligo
Expert dermatologists share approaches to treating patients with vitiligo, focusing on patient communication and the use of combination therapy.
Quality of Life for Vitiligo Patients
Heather Woolery-Lloyd, MD, comments on the emotional impact of vitiligo on patients’ quality of life.
Assessment of Vitiligo Severity
Ted Lain, MD, breaks down the use of the Vitiligo Area Scoring Index calculations to assess vitiligo severity.
Prevalence of Vitiligo
Drs Brittany Craiglow and Nada Elbuluk review the precipitating factors that trigger vitiligo, as well as segmental vs nonsegmental vitiligo.
Communication With Patients With Vitiligo
Iltefat Hamzavi, MD, explores key areas of patient communication that may shape adherence and outcomes in patients with vitiligo.
JAK Inhibitors for the Treatment of Vitiligo
Seemal R. Desai, MD, examines the mechanisms of JAK inhibitors and why these agents play an important role in the treatment of vitiligo.